

NFIL3 Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP16696a

Specification

NFIL3 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession

Q16649

NFIL3 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 4783

Other Names

Nuclear factor interleukin-3-regulated protein, E4 promoter-binding protein 4, Interleukin-3 promoter transcriptional activator, Interleukin-3-binding protein 1, Transcriptional activator NF-IL3A, NFIL3, E4BP4, IL3BP1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NFIL3 Antibody (N-term) Blocking Peptide - Protein Information

Name NFIL3

Synonyms E4BP4, IL3BP1

Function

Acts as a transcriptional regulator that recognizes and binds to the sequence 5'-[GA]TTA[CT]GTAA[CT]-3', a sequence present in many cellular and viral promoters. Represses transcription from promoters with activating transcription factor (ATF) sites. Represses promoter activity in osteoblasts (By similarity). Represses transcriptional activity of PER1 (By similarity). Represses transcriptional activity of PER2 via the B-site on the promoter (By similarity). Activates transcription from the interleukin-3 promoter in T-cells. Competes for the same consensus-binding site with PAR DNA-binding factors (DBP, HLF and TEF) (By similarity). Component of the circadian clock that acts as a negative regulator for the circadian expression of PER2 oscillation in the cell-autonomous core clock (By similarity). Protects pro-B cells from programmed cell death (By similarity). Represses the transcription of CYP2A5 (By similarity). Positively regulates the expression and activity of CES2 by antagonizing the repressive action of NR1D1 on CES2 (By similarity). Required for the development of natural killer cell precursors (By similarity).

Cellular Location



Tel: 858.875.1900 Fax: 858.875.1999

Nucleus {ECO:0000255|PROSITE-ProRule:PRU00978}.

Tissue Location

Expressed in bladder stomach, thyroid, spinal cord, lymph node, trachea, adrenal gland, bone marrow and muscle

NFIL3 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

NFIL3 Antibody (N-term) Blocking Peptide - Images

NFIL3 Antibody (N-term) Blocking Peptide - Background

Expression of interleukin-3 (IL3; MIM 147740) is restricted to activated T cells, natural killer (NK) cells, andmast cell lines. Transcription initiation depends on the activating capacity of specific protein factors, such as NFIL3, that bind toregulatory regions of the gene, usually upstream of thetranscription start site (Zhang et al., 1995 [PubMed7565758]).

NFIL3 Antibody (N-term) Blocking Peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010): Weng, Y.J., et al. Mol. Cell. Biochem. 340 (1-2), 187-194 (2010) :Lavebratt, C., et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (2), 570-581 (2010): Utge, S.J., et al. PLoS ONE 5 (2), E9259 (2010): Mansour, H.A., et al. Bipolar Disord 11(7):701-710(2009)